



Outcomes, Trends, and Healthcare Disparities in Patients Hospitalized with Chronic Limb-Threatening Ischemia

Christian Torres, MD¹; Francisco Ujueta, MD, MS¹; Everett Rogers, DO, MS²; Amre Ghazzal, MD¹; Radleigh Santos³; Christian Koelbl, MD, PhD¹; Esteban Escolar, MD¹; Gervasio A. Lamas, MD^{1,2}; Sahil A. Parikh, MD⁴; Nirat Beohar, MD¹

Abstract

BACKGROUND: Chronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease (PAD) and is associated with poor patient outcomes and increased healthcare costs. While racial, socioeconomic, and other healthcare disparities are widely recognized to influence the management of CLTI, the extent of the role they play is still an area of intense investigation.

METHODS: We analyzed data from the National Inpatient Sample (NIS) to identify all patients ≥ 18 years of age admitted with a primary diagnosis of CLTI from 2016 to 2019. Descriptive statistics were used to summarize patient baseline characteristics (age, gender, race, comorbidities, socioeconomic status, and procedural rates). Logistic regression models and temporal trends were used to determine predictors of major amputation and major adverse cardiovascular events (MACE), as well as in CLTI admissions during the 4-year study period, major amputation, endovascular intervention, and peripheral bypass further divided into racial cohorts.

RESULTS: A total of 121,087,650 patients were hospitalized from 2016 to 2019 of which 4,707,657 (3.9%) were hospitalized for CLTI. The mean age of patients admitted with CLTI was 60 ± 17 years. A majority were male (57.8%, $P < .001$), and White (72.0%, $P < .001$). They were more likely to be socioeconomically disadvantaged (32.8% with median household income 0-25th percentile, $P < .001$). Risk for hospitalization for CLTI varied inversely with increasing household income. During the hospitalization, 32.4% had invasive angiography, 0.6% had peripheral computed tomography angiogram (CTA), 3.3% underwent angioplasty, 1.6% peripheral bypass, and major amputation occurred in 9.2%. Black patients had the highest risk for amputation, followed by Native American and Hispanic patients. White patients made up the greatest percentage of CLTI admissions but were not at increased risk for amputation. Asian and Pacific Islander patients were the only racial group at decreased risk for amputation. Temporal trends during the 4-year period revealed the strongest predictors of MACE were diabetes and a history of peripheral angioplasty or peripheral bypass. Overall, there was a 6.7% increase in hospitalizations, a 14.1% increase in peripheral angioplasty rates, and an 8.4% decrease in peripheral bypass rates for CLTI during the 4-year study period. There was a reduction in above-the-knee amputation rates for all racial cohorts except for Native Americans (23.5% increase) during the study period. There was a 26.4% total increase in below-the-knee amputation rates.

CONCLUSION: Despite increased awareness of health disparities, poor outcomes resulting from CLTI (such as amputation) continue to disproportionately affect racial and socioeconomic minority groups. Revascularization and amputations during hospital admission for CLTI is increasing, driven by peripheral angioplasty and below-the-knee amputation, respectively.

J CRIT LIMB ISCHEM 2023;3(3):E103-E113. Epub 2023 September 18. doi: 10.25270/jcli/CLIG23-00019

Key words: Chronic limb-threatening ischemia, health disparities, peripheral artery disease, national inpatient sample

Background

Peripheral artery disease (PAD) is estimated to affect 236.6 million people over 25 years of age worldwide.¹ The most severe stage of PAD, chronic limb-threatening ischemia (CLTI), leads to increased cardiovascular mortality, lower extremity amputations, and, at the societal level, increased healthcare expenditures. Diabetes mellitus (DM), cigarette use, hypertension (HTN), hyperlipidemia, obesity, and sedentary lifestyle have been recognized as risk factors for CLTI.² Ethnic and racial disparities, and socioeconomic status also play a role in the outcomes of CLTI, with previous retrospective studies demonstrating greater odds of lower extremity amputation among Black patients compared with White patients.³⁻⁵ Previous studies have demonstrated that individuals with PAD are medically undertreated. For example, approximately 60% are treated with HMG-CoA reductase inhibitor (statin) therapy.^{3,6} However, the group predominantly affected by the underutilization of medical and catheter-based therapies are Black patients.⁷ It has been repeatedly shown that Black patients are less likely to undergo limb salvage therapy (ie, lower extremity revascularization), an important treatment in CLTI, likely resulting in the increased rates of lower extremity amputation.⁸ Health disparities are defined by preventable markers of health differences in a population group, such as ethnicity, race, sex, education level, geographic location, and household income.⁹ Although much focus has been placed on traditional risk factors such as HTN, diabetes, obesity, and tobacco cigarettes, other risk factors should be explored to continue to decrease the incidence and outcomes of CLTI. The 2021 American Heart Association (AHA) Statement of Peripheral Artery Disease and 2023 AHA Statement on Metal Contaminants identified nonconventional risk factors for PAD, which included urban areas and environmental contaminants (eg, air pollution, metal contaminants).^{10,11}

The purpose of the present study is to use the Nationwide Inpatient Sample (NIS) database to explore factors that contribute to racial and ethnic disparities in the treatment of CLTI. In addressing possible factors of disparities in CLTI we hope to answer: (1) What are the baseline characteristics of patients admitted to the hospital for CLTI?; (2) Are any of these characteristics able to help predict the risk of amputation and/or major adverse cardiovascular events (MACE)?; (3) Specifically, how do race and household income affect patient's risk for amputation or MACE?; and (4) How are amputation and revascularization rates for CLTI changing over time for the CLTI population as a whole, and for racial subgroups?

Methods

Data Source

Data were obtained from the NIS database from 2016 through 2019. The NIS is a publicly available database that is part of the Healthcare Cost and Utilization Project (HCUP) and sponsored by

the Agency for Healthcare Research and Quality (AHRQ) created with federal, state, and industry partnerships.¹ It is the largest publicly available all-payer inpatient healthcare database in the United States, yielding national estimates of inpatient hospital outcomes. It consists of a stratified sample of discharges from all hospitals in HCUP, and it equals approximately 20% of all discharges in US hospitals. Each hospitalization event included in the database represents a unique observation conformed by 1 primary discharge diagnosis and 29 secondary diagnoses during the index hospitalization. Using weights (DISCWT) provided by the NIS database, it estimates more than 35 million hospitalizations per year nationally.¹² Since the database contains de-identified patient information, the study was deemed exempt from the need for Institutional Review Board approval by our institution.

Study Population

Using International Classification of Diseases, Tenth Edition, Clinical Modification (ICD-10-CM) codes we identified all patients older than 18 years of age who were admitted between 2016 and 2019 with a primary diagnosis of CLTI (ICD-10th CM I7022, I7023, I7024, I7025, I7026, I7032, I7033, I7034, I7035, I7036, I7042, I7043, I7044, I7045, I7046, I7052, I7053, I7054, I7055, I7056, I7062, I7063, I7064, I7065, I7066, I7072, I7073, I7074, I7075, I7076).

Patient and Hospital Variables

Baseline characteristics, socioeconomic information, hospital characteristics, and demographics were obtained utilizing variables provided by the NIS database.¹² Socioeconomic data included median household income per quartiles. Demographics consisted of age, gender, and race. Relevant clinical variables were obtained using separate ICD-10 codes and Elixhauser clinical comorbidities as defined by the AHRQ.² Additionally, diagnostic tests and procedures such as computed tomography angiography (CTA), invasive peripheral angiography, peripheral angioplasty, peripheral bypass, and above- and below-the-knee amputation rates were obtained using the ICD-10-PCS codes. A detailed table of the ICD-10-CM and ICD-10-PCS codes used to identify patient comorbidities and procedures are provided in **Appendix Table 1**.

Outcomes Definition

We primarily sought to determine predictors of adverse outcomes (ie, major amputation and MACE), with the latter defined as death from any cause, myocardial infarction, coronary revascularization, hospitalization for angina, and stroke among patients hospitalized for CLTI, with a focus on evaluating for race/ethnic disparities and socioeconomic status during the study period. As secondary outcomes, we evaluated patient baseline and hospital characteristics (including hospital location [urban/rural], hospitalization costs, and length of stay). In addition, temporal trends in hospitalizations, amputations, and revascularization rates for patients with CLTI were assessed.

Statistical Analysis

Discharge weight provided by the NIS was applied to unweighted data to infer national estimates in accordance with HCUP regulation.¹³ Weighted data were used in all analyses. We used descriptive statistics to summarize the distribution of baseline parameters and hospital characteristics. Continuous variables were expressed as means or medians (costs), standard deviations, and 25th-75th percentiles, respectively, while categorical variables were expressed as absolute values with percentages. To ascertain differences between variables, we used the Pearson chi-square, Fisher's exact test, independent t-test, and Mann-Whitney U test as appropriate. Binary-logistic regression was used to explore the association between CLTI and inpatient outcomes. First, we performed a univariable analysis; variables that were significantly associated with our outcomes ($P < .2$) were included in our multivariable model to adjust for potential confounders. To estimate the temporal changes during the study period, we used time-series regression models. All statistical analyses were conducted using SPSS Statistics 27.0 (IBM Corp.). All P -values were two-sided, and statistical significance was defined as $P < .05$.

Results

A total of 121,087,650 patients were admitted for any cause during the 48-month study period between January 2016 and December 2019, of which 4,707,657 (3.9%) were admitted with CLTI. Overall admissions by race were 78,939,896 (65.2%) White, 17,814,860 (14.7%) Black, 13,044,454 (10.8%) Hispanic, 3,235,038 (2.7%) Asian, and 753,290 (.6%) Native American. There was a total of 4,707,657 patients admitted with CLTI, of which 3,303,328 (72%) were White, 565,430 (12.3%) Black, 499,675 Hispanic, 64,685 (1.4%) Asian, and 44,020 (1%) Native American.

Baseline Characteristics

The mean age of patients admitted with CLTI was 60 ± 17 years of age (standard deviation). Patients with CLTI were more likely to be male (57.8% vs 42.2%, $P < .001$). Both White (72.0% vs 65.2%, $P < .001$) and Native American patients (1.0% vs 0.6%, $P < .001$) made up a greater proportion of CLTI admissions compared to admissions for any cause. Compared with patients admitted for any cause, conversely, Black (12.3% vs 14.7%, $P < .001$) and Asian or Pacific Islander patients (1.4% vs 2.7%, $P < .001$) made up a smaller proportion of CLTI admissions compared to admissions for any cause. Although still statistically significant, rates of admission for Hispanic patients were roughly similar in both the CLTI and any cause groups (10.9% vs 10.8%, $P < 0.001$) (**Table 1**).

When divided by median household income quartiles, patients with CLTI were more likely to be economically disadvantaged. The highest percentage of patients (32.8%) were in the lowest income quartile (ie, median household income in the 0-25th percentile). The risk for hospitalization with CLTI decreased as household income increased. The most common comorbidities

TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS ADMITTED TO THE HOSPITAL WITH CHRONIC LIMB-THREATENING ISCHEMIA (2016-2019).

	Total = 4,707,657		P-value
	N	%	
Age (years \pm SD)	60 \pm 17		
Age Groups			
Age 18-40	718,545	15.30%	<.001
Age 41-60	1,612,894	34.30%	
Age 61-75	1,399,309	29.70%	
Age >75	977,549	20.80%	
Indicator of sex			
Male	2,719,883	57.80%	<.001
Female	1,987,774	42.20%	
Race			
White	3,303,328	72.00%	<.001
Black	565,430	12.30%	
Hispanic	499,675	10.90%	
Asian or Pacific Islander	64,685	1.40%	
Native American	44,020	1.00%	
Other	113,085	2.50%	
Length of stay (days \pm SD)	6 \pm 6		
Adjusted hospitalization cost			
Mean	\$8,754.28		<.001
26th & 75th percentile	\$5,234.77	\$15,214.98	
Median household income			
0-25th percentile	1,505,469	32.80%	<.001
26th to 50th percentile	1,237,929	27.00%	
51st to 75th percentile	1,054,250	23.00%	
76th to 100th percentile	789,985	17.20%	
Year			
2016	1,165,434	24.80%	<.001
2017	1,086,865	23.10%	
2018	1,212,999	25.80%	
2019	1,242,999	26.40%	

Continued on next page

among patients with CLTI included hypertension (47.3%), DM (43.2%), smoking (42.8%), hyperlipidemia (36.1%), and obesity (24.8%).

TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS ADMITTED TO THE HOSPITAL WITH CHRONIC LIMB-THREATENING ISCHEMIA (2016-2019).

	Total = 4,707,657		P-value
	N	%	
Disposition			
Routine	2,464,603	52.40%	<.001
Transfer to short-term hospital	96,205	2.00%	
Transfer other	955,030	20.30%	
Home health care	1,012,435	21.50%	
Hospital location			
Urban	4,191,269	89.00%	<.001
Rural	517,028	11.00%	
Admission type			
Non-elective admission	4,186,043	89.10%	<.001
Elective admission	513,294	10.90%	
Primary expected payer			
Medicare	2,397,294	51.00%	<.001
Medicaid	867,609	18.50%	
Private insurance	982,485	20.90%	
Comorbidities			
Diabetes	2,032,574	43.20%	<.001
Hypertension	2,227,089	47.30%	
Obesity	1,165,804	24.80%	
Smoking	2,016,159	42.80%	
Chronic lung disease	695,565	14.80%	
Hyperlipidemia	1,699,499	36.10%	
Chronic kidney disease	825,110	17.50%	
End-stage renal disease	367,660	7.80%	
Chronic liver disease	170,570	3.60%	
Heart failure	598,070	12.70%	
Pulmonary hypertension	143,975	3.10%	
Coronary artery disease	989,260	21.00%	
Prior PCI	23,100	0.50%	
Prior CABG	263,965	5.60%	
Solid cancer	139,720	3.00%	
Blood cancer	63,425	1.30%	
Stroke	16,780	0.40%	

TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS ADMITTED TO THE HOSPITAL WITH CHRONIC LIMB-THREATENING ISCHEMIA (2016-2019).

	Total = 4,707,657		P-value
	N	%	
Procedures			
Peripheral angiogram	130,670	32.4%	<.001
Computed tomography angiogram	2320	0.6%	
Peripheral MR angiogram	155	0.00%	
Peripheral arterial ultrasound	5910	1.50%	
Peripheral angioplasty	154,455	3.30%	
Peripheral bypass	77,985	1.70%	
Above-the-knee amputation	38,735	0.80%	
Below-the-knee amputation	396,545	8.40%	

SD = standard deviation; CABG = coronary arterial bypass graft; MR = magnetic resonance; PCI = percutaneous coronary intervention.

In terms of procedures, 32.4% of patients admitted with CLTI underwent invasive angiography, 0.6% had peripheral CTA, 3.3% peripheral angioplasty, and 1.6% underwent peripheral bypass during index hospitalization. Major amputation occurred in 9.2% of patients; 0.8% of patients underwent above-the-knee amputation (AKA) and 8.4% underwent below-the-knee amputation (BKA) during index hospitalization.

Predictors of Amputation

The age group with the largest number of patients (between 41 and 60 years) had the highest risk for amputation (adjusted odds ratio [aOR] 1.41, 95% confidence interval [CI]: 1.40-1.43, $P < .001$) (**Table 2, Figure 1**). Women were significantly less likely to undergo amputation (aOR 0.59, 95% CI: 0.58-0.59, $P < .001$). Among racial cohorts, Black patients were at the highest risk for undergoing amputation during hospitalization (aOR 1.37, 95% CI: 1.34-1.39, $P < .001$), followed by Native American (aOR 1.37, 95% CI: 1.32-1.42, $P < .001$) and Hispanic (aOR 1.12, 95% CI: 1.10-1.14, $P < .001$) patients. White patients were not at increased risk for amputation (aOR 1.00, 95% CI: 0.99-1.02, $P = .860$), and Asian and Pacific Islander patients were the only racial group at decreased risk for amputation (aOR 0.80, 95% CI: 0.77-0.83, $P < .001$) (**Table 3**).

Just as patients from lower socioeconomic households were more likely to be hospitalized with CLTI, they were also more likely to undergo amputation during index hospitalization (aOR 1.25, 95% CI: 1.23-1.28, $P < .001$). We found this risk to be sequentially stratified. In other words, progressively lower median

TABLE 2. MULTIVARIATE PREDICTORS OF AMPUTATION IN PATIENTS ADMITTED WITH CHRONIC LIMB THREATENING ISCHEMIA (2016-2019).

Variables	aOR	95% CI	P-value
Age 18-40	0.75	0.74-0.76	<.001
Age 41-60	1.41	1.40-1.43	<.001
Age 61-75	1.30	1.29-1.32	<.001
Female	0.59	0.58-0.59	<.001
African American	1.37	1.34-1.39	<.001
White	0.86	0.99-1.02	=.86
Hispanic	1.12	1.10-1.14	<.001
Asian	0.80	0.77-0.83	<.001
Native American	1.37	1.32-1.42	<.001
Urban	0.77	0.76-0.78	<.001
Diabetes	4.15	4.12-4.19	<.001
Hypertension	1.13	1.12-1.13	<.001
Obesity	0.66	0.65-0.67	<.001
Smoking	1.08	1.07-1.08	<.001
Chronic lung disease	0.79	0.78-0.79	<.001
Hyperlipidemia	1.15	1.15-1.16	<.001
Chronic kidney disease	1.23	1.22-1.24	<.001
End-stage renal disease	1.35	1.34-1.37	<.001
Chronic liver disease	0.57	0.56-0.59	<.001
Heart failure	0.76	0.75-0.77	<.001
Atrial arrhythmias	0.89	0.88-0.90	<.001
Coronary artery disease	1.17	1.16-1.18	<.001
Prior PCI	0.94	0.90-0.98	<.001
Stroke	0.62	0.58-0.66	<.001
Prior CABG	1.04	1.03-1.05	<.001
0-25th percentile	1.25	1.23-1.28	<.001
26-50th percentile	1.23	1.20-1.26	<.001
51-75th percentile	1.18	1.15-1.21	<.001
76-100th percentile	1.05	1.02-1.07	<.001
Peripheral angioplasty	3.10	3.06-3.14	<.001
Peripheral bypass	1.61	1.58-1.64	<.001

aOR = adjusted odds ratio; CI = confidence interval; CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention.

TABLE 3. MULTIVARIATE PREDICTORS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS ADMITTED WITH CHRONIC LIMB THREATENING ISCHEMIA (2016-2019).

Variables	aOR	95% CI	P-value
Age 18-40	0.12	0.11-0.13	<.001
Age 41-60	0.41	0.40-0.42	<.001
Age 61-75	0.7	0.69-0.71	<.001
Female	1.02	1.00-1.04	=.012
African American	0.89	0.86-0.93	<.001
White	0.93	0.90-0.96	<.001
Hispanic	0.8	0.76-0.83	<.001
Asian	1.35	1.26-1.44	<.001
0-25th percentile	1.07	1.01-1.13	=.013
26-50th percentile	1.03	0.98-1.09	=.237
51-75th percentile	0.95	0.90-1.00	=.049
76-100th percentile	0.9	0.85-0.95	<.001
Native American	0.99	0.90-1.08	=.769
Urban hospital	0.98	0.95-1.00	=.127
Diabetes	1.07	1.06-1.09	<.001
Hypertension	0.89	0.87-0.89	<.001
Obesity	0.83	0.81-0.85	<.001
Smoking	0.87	0.86-0.89	<.001
Chronic lung disease	0.98	0.96-0.99	=.017
Hyperlipidemia	1.04	1.03-1.06	<.001
Chronic kidney disease	1.03	1.02-1.05	<.001
End-stage renal disease	1.28	1.25-1.31	<.001
Chronic liver disease	1.26	1.21-1.31	<.001
Heart failure	1.61	1.57-1.64	<.001
Atrial arrhythmias	1.26	1.23-1.28	<.001
Coronary artery disease	2.46	2.41-2.50	<.001
Prior PCI	0.92	0.86-0.99	=.038
Prior CABG	0.86	0.84-0.88	<.001
Peripheral angioplasty	1.14	1.10-1.18	<.001
Peripheral bypass	1.25	1.19-1.31	<.001
Above-the-knee amputation	1.7	1.60-1.79	<.001
Below-the-knee amputation	0.59	0.57-0.60	<.001

aOR = adjusted odds ratio; CI = confidence interval; CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention.




FIGURE 1. Forest plot of predictors of amputation in patients admitted with chronic limb-threatening ischemia (2016-2019). CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention.

household income quartile was associated with increased risk for amputation (**Table 3**).

While the most common baseline characteristics of patients admitted with CLTI were well recognized atherogenic risk factors, the top 3 predictors of amputation included DM (aOR 4.15, 95% CI: 4.12-4.19, $P < .001$), history of peripheral angioplasty (aOR 3.10, 95% CI: 3.06-3.14, $P < .001$), and history of peripheral bypass (aOR 1.61, 95% CI: 1.58-1.64, $P < .001$) (**Table 3**).

Predictors of MACE

In contrast to predictors of amputation, age was not a significant predictor of in-hospital MACE risk (**Table 3, Figure 2**). Asian and Pacific Islanders were the only racial cohort at increased risk for MACE during hospitalization (aOR 1.35, 95% CI: 1.27-1.44, $P < .001$). The risk for MACE was again sequentially stratified among the different socioeconomic groups, with the lowest socioeconomic households being the only stratum at increased risk (aOR 1.07, 95% CI: 1.02-1.13, $P = .013$).

Overall, the top 3 predictors of MACE in patients admitted with CLTI were coronary artery disease (aOR 2.46, 95% CI: 2.41-2.50, $P < .001$), history of AKA (aOR 1.70, 95% CI: 1.61-1.79, $P < .001$), and heart failure (aOR 1.61, 95% CI: 1.57-1.64, $P < .001$) (**Table 2**).

Temporal Trends

Despite an initial downward trend in admissions for CLTI from 2016 to 2017, there was an overall 6.7% increase in CLTI admissions during the study period (**Figure 3**). Major amputations increased by 22.7% during the study period, driven by a 26.4% increase in BKA. The increase in BKA was seen in all racial cohorts. White patients saw the largest increase in BKA in terms of raw numbers (16,340 more procedures performed in 2019 compared with 2016), while Native Americans saw the largest percent increase (51.96% more procedures performed in 2019 compared with 2016). AKA decreased by 8.71% during the study period, driven largely by a reduction in AKA among Black patients. A reduction in AKA was seen in all racial cohorts, except for Native Americans, who experienced a 23.5% increase in AKA, although the total number of AKA performed in this population was very low.

Discussion

In a large population-based study, the following were the principal findings: 1) A majority of patients were White males and were more likely to be socioeconomically disadvantaged. 2) The risk for hospitalization for CLTI varied inversely with




FIGURE 2. Forest plot of predictors of major adverse cardiovascular events in patients admitted with chronic limb-threatening ischemia (2016-2019). CABG = coronary artery bypass grafting; PCI= percutaneous coronary intervention.

increasing household income. 3) During hospitalization, catheter-based or surgical revascularization was infrequent, and major amputation was 3 times more likely than revascularization. 4) Black patients had the highest risk for amputation, followed by Native American and Hispanic patients. White patients were not at increased risk for amputation, and Asian and Pacific Islander patients were the only racial group at decreased risk for amputation. 5) The strongest predictors of MACE were DM and a history of prior peripheral revascularization. 6) There was an overall increase in hospitalizations and peripheral angioplasty rates, but a decrease in peripheral bypass rates for CLTI during the study period. 7) There was a reduction in AKA rates for all racial cohorts except for Native Americans, but an increase in BKA rates for all racial subgroups.

The present study demonstrated that household income and ethnic disparities are risk factors in lower extremity amputation and in-hospital mortality in patients admitted for PAD-CLTI. In particular, Black and Native Americans appear to be the ethnic groups impacted the greatest. Known risk factors such as DM and

a history of lower extremity revascularization have the highest predictive value for lower extremity amputation; patients with DM have a 4 times greater risk, odds ratio (aOR 4.15 [4.12-4.19]). It was also suggested that patients undergoing peripheral angioplasty have a 3 times higher risk of lower extremity amputation (aOR 3.10 [3.06-3.14]). Admissions for CLTI are on the rise, which may be due to increased awareness in identifying this patient population or under management of the disease with subsequent progression to CLTI and eventually amputation. The majority of CLTI admissions occur in urban compared with suburban hospitals, which could be due to the increased population density or increased individual exposure to risk factors such as air pollution (such as $PM_{2.5}$) and metal contaminants (eg, cadmium and lead, found in water, food, and air pollution).¹⁴⁻¹⁶

Black individuals are known to have a 2- to 3-fold higher prevalence of PAD^{17,18} compared with White individuals.^{19,20} These racial differences may be due to the higher prevalence of traditional risk factors in Black individuals, such as DM, obesity, and smoking. Previous studies have shown that Black individuals




FIGURE 3. Yearly trends of patients admitted with chronic limb-threatening ischemia (2016-2019).

are more likely to smoke tobacco products and less likely to stop smoking compared with non-Hispanic White individuals.^{21,22} Despite the increased prevalence of atherogenic risk factors in the Black population, epidemiological studies have not implicated these factors as the sole reason for the increased prevalence of PAD and disproportionately poor outcomes seen in this group.²³ This observation is supported by an analysis of the National Health and Nutritional Examination Survey from 1999 to 2000, which included over 2000 participants over 40 years of age. It demonstrated that Black individuals have an approximately 3 times higher associated prevalence of PAD compared with non-Hispanic White individuals (OR 2.83), even after accounting for smoking status, DM, body mass index, glomerular filtration rate, and hypercholesterolemia.²⁴ Thus, although traditional therapies and interventions have focused on decreasing conventional risk factors of PAD, nontraditional risk factors such as environmental pollutants, race, socioeconomic status, and certain comorbidities (including depression, elevated lipoprotein (a), and chronic kidney disease [CKD]) may be playing a role in the increased prevalence and likely outcomes in PAD-CLTI.

Our results are consistent with prior studies revealing low household income being a risk factor for worse outcomes and lower extremity amputations.³⁻⁵ This study suggests that Americans in the lowest income quartile account for almost one-third of admissions for CLTI and have the highest risk for amputation and MACE. In addition, the lowest quartile income is also at a 25% increased risk of major nontraumatic amputations. Although PAD-CLTI continues to be underrecognized and undertreated by the medical community, Black patients are disproportionately undertreated with optimal medical therapy compared with other ethnicities. A study using electronic health records from the University of Michigan Health system demonstrated that 62% of Black patients were prescribed a statin, despite having a higher atherosclerotic risk score.²⁵ A similar study from Emory University revealed a 66.7% statin prescription rate for Black patients with PAD vs 73.4%, $P < .0001$ for all other racial groups.²⁶ Antiplatelets have also been shown to be underutilized in this population. One single-center study from Guber et al revealed that

100% of patients discharged without antiplatelets were Black.²⁷ In addition, several studies have demonstrated that Black patients are less likely to be offered limb salvage therapies such as revascularization.²⁸⁻³¹ Thus, this raises the question, is it provider bias, patient access to optimal medical therapy, or a system failure in providing optimal medical management to Black patients with PAD-CLTI that results in the increased prevalence of CLTI, and eventual lower extremity amputations seen in this population?

Social determinants of health do not only include household income or access to healthcare as suggested previously, but also housing. It has been suggested that biological mechanisms such as a proinflammatory state and endothelial oxidative stress likely play a role in the disparity,³² but one must look further. In 2021, the AHA identified air pollution (eg, PM_{2.5}) and heavy metals (such as lead and cadmium) as nontraditional risk factors for PAD, and a 2023 AHA Scientific Statement reaffirmed metal contaminants as cardiovascular risk factors.^{11,16} The majority of Black individuals are located in the urban cities of the United States, closer to major roadways and industrialization, which exposes them to daily environmental insults, which we now know increases cardiovascular mortality. Environmental contaminants such as cadmium and lead are 2 well-known cardiovascular vasculotoxins, which cause endothelial dysfunction and increase reactive oxygen species and inflammatory factors, resulting in atherosclerosis. Lead production increased during the turn of the 20th century, with extensive industrial and public use, including lead gasoline and household paint, in addition to being found in tobacco cigarettes. Interestingly, although smoking cessation decreases the risk of PAD-CLTI, a study has shown that it takes 30 years for an individual's risk to reach that of a never smoker,³³ and the half-life of cadmium and lead in the human body is approximately 30 years. Cadmium has the strongest association with PAD. Our group previously published a study in patients with coronary artery disease, demonstrating urinary cadmium was lowest in those without PAD, higher in individuals with PAD, and highest in CLTI individuals.¹⁵ Thus, although our focus has helped decrease conventional risk factors in PAD-CLTI, our continued exposure to non-traditional risk factors may be a modifiable means to curb the increasing incidence. There is a great need for public health interventions through legislation to control these risk factors and to minimize the inciting exposure of air pollution and metal contamination in the water, soil, and food.³³

Native Americans

Our study also revealed an increased rate of major amputations in Native Americans inpatients admitted with CLTI. The Strong Heart Study, a population-based cohort study in 12 Native American communities recruited between 1989-1991, has demonstrated in various published studies the interaction between environmental contaminants and increased cardiovascular disease.¹⁴ In a recent statement, the AHA identified metal contaminants, particularly

lead and cadmium, as cardiovascular risk factors in this ethnic population.^{34,35} The source of this metal contamination is likely water wells and dietary sources, which heightens the importance of safe accessible drinking water.^{36,37}

Study Limitations

Similar to any retrospectively collected data set, the study may include biases related to possible erroneous diagnosis or diagnostic misclassification or underreporting. These errors may have been more pronounced in the study considering the NIS relies on ICD-10-CM codes. Proper diagnosis of CLTI by general clinicians can be difficult, though the noted increase in CLTI hospitalization may in part be related to increased recognition. Some factors are not able to be objectively captured by the NIS database. For example, some patient characteristics, such as race, are self-reported, leading to potential reporting bias. Furthermore, the NIS only captures procedures that were performed during the index admission. Therefore, if a patient admitted with CLTI were discharged and underwent a procedure in the outpatient setting, our data would not capture the event and lead to underreporting. This is of importance as peripheral vascular interventions are being done in outpatient base catheterization labs. Similarly, if a patient were discharged from the hospital and suffered a MALE or MACE sometime later, our data is not able to associate that event with the index CLTI admission.

Conclusions

The rates of CLTI increased during our 4-year review of the NIS database. While AKA and peripheral bypass rates are decreasing, the number of BKA and peripheral angioplasties performed for CLTI are significantly increasing. It is important for future studies to continue to monitor these trends, particularly in the context of recently published data from the Best Endovascular Versus Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial, suggesting that surgical revascularization may lead to more favorable outcomes in patients with CLTI for whom both surgical and endovascular intervention is feasible.³⁸ The findings of BEST-CLI stand in contrast with those of the BASIL-2 trial, which demonstrated better amputation-free survival rates in patients with CLTI due to infrapopliteal disease undergoing endovascular treatment, as opposed to vein bypass, as a first attempt at revascularization. However, one of the major criticisms of BASIL-2 was its open-label design. Thus, more studies are needed to resolve the question of the best approach to revascularization in this complex group of patients.³⁹ DM and a history of previous revascularization procedures are the most important predictors of increasing in-hospital lower extremity amputations. Among racial and socioeconomic cohorts, individuals in the lowest quartile of household income and Black and Native American individuals have the highest risk of nontraumatic major lower extremity

amputations. We must look at modifiable nontraditional risk factors such as environmental contaminants, reimbursements, wound care, obesity education, socioeconomic impediments to medical care, and certain comorbidities (including depression, elevated lipoprotein (a), and CKD) as an additional source to continue decreasing our rates of cardiovascular events in CLTI. In addition, we need to continue to expand and improve the delivery of accessible clinical care to all individuals, regardless of race, sex, or socioeconomic status. Additional clinical trials and community studies are needed to further understand the racial disparities and potential interventions needed to decrease the risk of negative limb outcomes and improve health equity.

References

1. Tsao CW, Aday AW, Almarazooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. *Circulation*. 2022;145(8):e153-e639. doi:10.1161/CIR.0000000000001052
2. Durazzo TS, Frencher S, Gusberg R. Influence of race on the management of lower extremity ischemia: revascularization vs amputation. *JAMA Surg*. 2013;148(7):617-623. doi:10.1001/jamasurg.2013.1436
3. Nguyen LL, Hevelone N, Rogers SO, et al. Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss. *Circulation* 2009;119(1):123-130. doi:10.1161/CIRCULATIONAHA.108.810341
4. Jones WS, Patel MR, Dai D, et al. Temporal trends and geographic variation of lower-extremity amputation in patients with peripheral artery disease: results from U.S. Medicare 2000-2008. *J Am Coll Cardiol*. 2012;60(21):2230-2236. doi:10.1016/j.jacc.2012.08.983
5. Rivero M, Nader ND, Blochle R, Harris LM, Dryjski ML, Dosluglu HH. Poorer limb salvage in African American men with chronic limb ischemia is due to advanced clinical stage and higher anatomic complexity at presentation. *J Vasc Surg*. 2016;63(5):1318-1324. doi:10.1016/j.jvs.2015.11.052
6. Foley TR, Singh GD, Kokkinidis DG, et al. High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease. *J Am Heart Assoc*. 2017;6(7):e005699. doi:10.1161/JAHA.117.005699
7. Nanna MG, Navar AM, Zakrofsky P, et al. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the Patient and Provider Assessment of Lipid Management Registry. *JAMA Cardiol*. 2018;3(8):739-748. doi:10.1001/jamacardio.2018.1511
8. Hughes K, Boyd C, Oyetunji T, et al. Racial/ethnic disparities in revascularization for limb salvage: an analysis of the National Surgical Quality Improvement Program database. *Vasc Endovascular Surg*. 2014;48(5-6):402-405. doi:10.1177/1538574414543276
9. Francis DK, Bennett NR, Ferguson TS et al. Disparities in cardiovascular disease among Caribbean populations: a systematic literature review. *BMC Public Health*. 2015;15:828. doi:10.1186/s12889-015-2166-7
10. Criqui MH, Matsushita K, Aboyans V, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. *Circulation* 2021;144(9):e171-e191. doi:10.1161/CIR.0000000000001005
11. Lamas GA, Bhatnagar A, Jones MR, et al. Contaminant metals as cardiovascular risk factors: a scientific statement from the American Heart Association. *J Am Heart Assoc*. 2023;12(13):e029852. doi:10.1161/JAHA.123.029852
12. Houchens RL, Elixhauser A. Using the HCUP Nationwide Inpatient Sample to Estimate Trends. HCUP Methods Series Report # 2005-01. U.S. Agency for Healthcare Research and Quality. 2005. <http://www.hcup-us.ahrq.gov/reports/methods.jsp>

13. Agency for Healthcare Research and Quality. HCUP overview. Healthcare Cost and Utilization Project (HCUP). <https://hcup-us.ahrq.gov/overview.jsp>.
14. Kuo CC, Balakrishnan P, Gribble MO, et al. The association of arsenic exposure and arsenic metabolism with all-cause, cardiovascular and cancer mortality in the Strong Heart Study. *Environ Int*. 2022;159:107029. doi:10.1016/j.envint.2021.107029
15. Ujueta F, Arenas IA, Diaz D, et al. Cadmium level and severity of peripheral artery disease in patients with coronary artery disease. *Eur J Prev Cardiol*. 2019;26(13):1456-1458. doi:10.1177/2047487318796585
16. Cardoso CRL, Melo JV, Santos TRM, Leite NC, Salles GF. Traditional and non-traditional risk factors for peripheral artery disease development/progression in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. *Cardiovasc Diabetol*. 2021;20:54. doi:10.1186/s12933-021-01249-y
17. Allison MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. *Am J Prev Med*. 2007;32(4):328-333. doi:10.1016/j.amepre.2006.12.010
18. Loja MN, Brunson A, Li CS, et al. Racial disparities in outcomes of endovascular procedures for peripheral arterial disease: an evaluation of California hospitals, 2005-2009. *Ann Vasc Surg*. 2015;29(5):950-959. doi:10.1016/j.avsg.2015.01.006
19. Aronow WS. Prevalence of atherothrombotic brain infarction, coronary artery disease and peripheral arterial disease in elderly blacks, Hispanics and whites. *Am J Cardiol*. 1992;70(13):1212-1213. doi:10.1016/0002-9149(92)90059-8
20. Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM. The prevalence of peripheral arterial disease in a racially diverse population. *Arch Intern Med*. 2003;163(12):1469-1474. doi:10.1001/archinte.163.12.1469
21. Safford MM, Brown TM, Muntner PM, et al. Association of race and sex with risk of incident acute coronary heart disease events. *JAMA*. 2012;308(17):1768-1774. doi:10.1001/jama.2012.14306
22. Caraballo RS, Kruger J, Asman K, et al. Relapse among cigarette smokers: the CARDIA longitudinal study - 1985-2011. *Addict Behav*. 2014;39(1):101-106. doi:10.1016/j.addbeh.2013.08.030
23. Criqui MH, Vargas V, Denenberg JO, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. *Circulation*. 2005;112(17):2703-2707. doi:10.1161/CIRCULATIONAHA.105.546507
24. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. *Circulation*. 2004;110(6):738-473. doi:10.1161/01.CIR.0000137913.26087.F0
25. Dorsch MP, Lester CA, Ding Y, Joseph M, Brook RD. Effects of race on statin prescribing for primary prevention with high atherosclerotic cardiovascular disease risk in a large healthcare system. *J Am Heart Assoc*. 2019;8(22):e014709. doi:10.1161/JAHA.119.014709
26. Arya S, Binney Z, Khakharia A, et al. Race and socioeconomic status independently affect risk of major amputation in peripheral artery disease. *J Am Heart Assoc*. 2018;7(2):e007425. doi:10.1161/JAHA.117.007425
27. Gober L, Bui A, Ruddy JM. Racial and gender disparity in achieving optimal medical therapy for inpatients with peripheral artery disease. *Ann Vasc Med Res*. 2020;7(4):1115.
28. Hughes K, Seetahal S, Oyetunji T, et al. Racial/ethnic disparities in amputation and revascularization: a nationwide inpatient sample study. *Vasc Endovascular Surg*. 2014;48(1):34-37. doi:10.1177/1538574413510618
29. Guadagnoli E, Ayanian JZ, Gibbons G, McNeil BJ, LoGerfo FW. The influence of race on the use of surgical procedures for treatment of peripheral vascular disease of the lower extremities. *Arch Surg*. 1995;130(4):381-386. doi:10.1001/archsurg.1995.01430040043006
30. Huber TS, Wang JG, Wheeler KG, et al. Impact of race on the treatment for peripheral arterial occlusive disease. *J Vasc Surg*. 1999;30(3):417-425. doi:10.1016/s0741-5214(99)70068-6
31. Newhall K, Spangler E, Dzebisashvili N, Goodman DC, Goodney P. Amputation rates for patients with diabetes and peripheral arterial disease: the effects of race and region. *Ann Vasc Surg*. 2016;30:292-298.e1. doi:10.1016/j.avsg.2015.07.040
32. Gardner AW, Parker DE, Montgomery PS, et al. Gender and racial differences in endothelial oxidative stress and inflammation in patients with symptomatic peripheral artery disease. *J Vasc Surg*. 2015;61(5):1249-1257. doi:10.1016/j.jvs.2014.02.045
33. Ding N, Sang Y, Chen J, et al. Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. *J Am Coll Cardiol*. 2019;74(4):498-507. doi:10.1016/j.jacc.2019.05.049
34. Nigra AE, Chen Q, Chillrud SN, et al. Inequalities in public water arsenic concentrations in counties and community water systems across the United States, 2006-2011. *Environ Health Perspect*. 2020;128(12):127001. doi:10.1289/EHP7313
35. Breathett K, Sims M, Gross M, et al. Cardiovascular health in American Indians and Alaska Natives: a scientific statement from the American Heart Association. *Circulation*. 2020;141(25):e948-e959. doi:10.1161/CIR.0000000000000773
36. Spaur M, Lombard MA, Ayotte JD, et al. Associations between private well water and community water supply arsenic concentrations in the conterminous United States. *Sci Total Environ*. 2021;787:147555. doi:10.1016/j.scitotenv.2021.147555
37. Thomas ED, Gittelsohn J, Yracheta J, et al. The Strong Heart Water Study: informing and designing a multi-level intervention to reduce arsenic exposure among private well users in Great Plains Indian Nations. *Sci Total Environ*. 2019;650(Pt 2):3120-3133. doi:10.1016/j.scitotenv.2018.09.204
38. Farber A, Menard MT, Conte MS, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. *N Engl J Med*. 2022;387(25):2305-2316. doi:10.1056/NEJMoa2207899
39. Bradbury AW, Moakes CA, Popplewell M, et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. *Lancet*. 2023;401(10390):1798-1809. doi:10.1016/S0140-6736(23)00462-2

From ¹Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, Florida; ²Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida; ³Department of Mathematics, 2814NSU NOVA Southeastern University, Fort Lauderdale, Florida; ⁴Center for Interventional Cardiovascular Care, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.

Correspondence: Nirat Beohar, MD, Professor of Medicine, Columbia University Medical Center, Columbia University Division of Cardiology, Mount Sinai Medical Center, 4300 Alton Road, Suite 2070, Miami Beach, FL 33140. Email: Nirat.Beohar@msmc.com

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Declaration of conflicting interests: Dr. Parikh reports serving on the advisory boards of Abbott Vascular, Boston Scientific, Cordis, Medtronic, and Philips. He receives institutional research support from Abbott, Acotec, Boston Scientific, Concept Medical, Shockwave Medical, Surmodics, and Trirème Medical. He is a consultant to Abiomed, Canon, Inari, Penumbra, and Terumo. He has equity stake in Advanced Nanotherapies, eFemoral, and Encompass Vascular.

Supplemental Material

APPENDIX TABLE 1: ICD-10-CM/PCS 10 CODES.	
Disease/Procedure	ICD-10-CM/PC codes
Critical limb-threatening ischemia	I7022, I7023, I7024, I7025, I7026, I7032, I7033, I7034, I7035, I7036, I7042, I7043, I7044, I7045, I7046, I7052, I7053, I7054, I7055, I7056, I7062, I7063, I7064, I7065, I7066, I7072, I7073, I7074, I7075, I7076
Diabetes	E11
Hypertension	I10, I11, I12, I13, I15, I16
Obesity	E66
Stroke	I61, I63, Z8673
Hyperlipidemia	E78
Smoking	F17, F172, F1720, F17200, 7201, F17203, F17208, F17209, F1721, F17210, F17211, F17213, F17218, F17219, F1722, F17220, F17221, F17223, F17228, F17229, F1729, F17290, F17291, F17293, F17298
Chronic liver disease	K74, K70, K71, K76
Chronic lung disease	J40, J41, J42, J43, J44
Chronic kidney disease	N18
End-stage renal disease	N186, Z992, 5A1D7, 5A1D70, 5A1D70Z, 5A1D8, 5A1D80, 5A1D80Z, 5A1D9, 5A1D90, 5A1D90Z
Congestive heart failure	I50
Atrial Arrhythmias	I48
Coronary artery disease	I25
Prior percutaneous intervention	Z9861
Prior coronary artery bypass grafting	Z951, I257, I25810, I25812
Diagnostics and procedures	
Peripheral angiography	B41JZZZ, B41JYZZ, B41JY10, B41J1ZZ, B41J110, B41J0ZZ, B41J010, B41GZZZ, B41GYZZ, B41GY10, B41G1ZZ, B41G110, B41G0ZZ, B41G010, B41F010, B41F0ZZ, B41F110, B41F1ZZ, B41FY10, B41FYZZ, B41FZZZ, B41C010, B41C0ZZ, B41C110, B41C1ZZ, B41CY10, B41CYZZ, B41CZZZ.
Computed tomography angiography	B42C0ZZ, B42C1ZZ, B42CYZZ, B42CZZZ, B42F0ZZ, B42F1ZZ, B42FYZZ, B42FZ2Z, B42FZZZ, B42G0ZZ, B42G1ZZ, B42GYZZ, B42GZ2Z, B42GZZZ, B42H0ZZ, B42H1ZZ, B42HYZZ, B42HZZZ.
Magnetic resonance angiography	B43CY0Z, B43CYZZ, B43CZZZ, B43FY0Z, B43FYZZ, B43FZZZ, B43GY0Z, B43GYZZ, B43GZZZ, B43HY0Z, B43HYZZ, B43HZZZ
Peripheral arterial ultrasound	B44FZZZ, B44GZZZ, B44HZZZ, B44KZZZ, B44LZZZ
Peripheral bypass	041C, 041D, 041E, 041F, 041H, 041J, 041K, 041L, 041M, 041N, 041P, 041Q, 041R, 041S, 041T, 041U, 041V, 041W
Peripheral angioplasty	047C3, 047C4, 047C3, 047C4, 047D3, 047D4, 047E3, 047E4, 047F3, 047F4, 047H3, 047H4, 047J3, 047J4, 047K3, 047J4, 047L3, 047L4, 047M3, 047M4, 047N3, 047N4, 047P3, 047P4, 047Q3, 047Q4, 047R3, 047R4, 047S3, 047S4, 047T3, 047T4, 047U3, 047U4, 047V3, 047V4, 047W3, 047W4, 047Y3, 047Y4
Above-the-knee amputation	OY62, OY63, OY64, OY67, OY68, OY68, OY6C, OY6D, OY6F, OY62G
Below-the-knee amputation	OY6H, OY6J, OY6N, OY6P, OY6Q, OY6R, OY6S, OY6T, OY6U, OY6V, OY6W, OY6X, OY6Y